[^18F]FDG 마이크로 PET/MR 이미징을 사용한 마우스의 갈색 및 베이지 지방 조직의 시각화 및 정량화

Executive Industry Relevance

Quantitative PET/MR imaging of brown and beige adipose tissues in mice enables precise, non-invasive assessment of thermogenic depot activity, supporting early-stage metabolic target validation. This approach enhances predictive confidence in preclinical models by providing functional and anatomical data critical for obesity and metabolic syndrome research. Integration of these imaging outputs informs portfolio decisions and de-risks translational advancement of metabolic therapeutics.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables functional interrogation of thermogenic adipose tissue activity in vivo.
• Supports biological de-risking by quantifying depot-specific metabolic responses.
• Facilitates target validation for metabolic disease pathways using quantitative imaging endpoints.
• Provides mechanistic insight into compensatory activation of beige adipocytes following brown adipose tissue removal.

Screening & Assay Development

• Establishes validated imaging protocols for reproducible quantification of depot activity.
• Standardizes animal positioning and imaging parameters to ensure assay consistency.
• Delivers quantitative readouts suitable for comparative compound evaluation in metabolic studies.
• Enables scalability through potential high-throughput imaging of multiple animals.

Translational & Preclinical Research

• Aligns preclinical imaging outputs with translational biomarker strategies for metabolic disorders.
• Supports continuity from discovery through preclinical validation by linking functional imaging to depot-specific outcomes.
• Provides risk-adjusted data for advancing metabolic targets toward clinical development.
• Enhances predictive de-risking by correlating imaging findings with morphological adipocyte changes.

Pipeline & Workflow Integration

This PET/MR imaging protocol fits within the early discovery to preclinical validation continuum for metabolic disease research, enabling robust target evaluation and mechanistic de-risking.

• Discovery Biology: Quantifies thermogenic activity and depot mobilization to clarify metabolic pathway engagement.
• Screening: Provides standardized, reproducible imaging assays for functional evaluation of candidate interventions.
• Analytics: Generates quantitative [¹⁸F]FDG uptake data for statistical comparison across experimental groups.
• Translational Research: Bridges preclinical imaging findings to human metabolic biomarker strategies when supported by data.
• Enterprise Reuse: Offers a transferable imaging workflow adaptable to various metabolic disease models and intervention studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in metabolic target validation.
• Operational Value: Delivers standardized, scalable imaging protocols for reproducible data generation.
• Strategic Value: Informs go/no-go decisions and optimizes resource allocation in metabolic disease portfolios.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of metabolic therapeutic candidates.

Implementation Considerations

• Requires expertise in small animal PET/MR imaging and radiotracer handling.
• Demands access to calibrated PET/MR instrumentation and analytical software for quantitative analysis.
• Necessitates rigorous standardization of animal positioning and imaging parameters across studies.
• Adaptation to other preclinical models may require protocol optimization for anatomical and metabolic differences.
• Imaging throughput and statistical power can be increased by simultaneous scanning of multiple animals.

Biopharma FAQs